SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:45106413-6b59-4525-9ffd-390f22fec90b"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:45106413-6b59-4525-9ffd-390f22fec90b" > Effects of the DPP-...

Effects of the DPP-4 Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects with Impaired Glucose Tolerance

Rosenstock, J (författare)
Foley, J E (författare)
Rendell, M (författare)
visa fler...
Landin-Olsson, Mona (författare)
Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
Holst, J J (författare)
Deacon, C F (författare)
Rochotte, E (författare)
Baron, M A (författare)
visa färre...
 (creator_code:org_t)
American Diabetes Association, 2008
2008
Engelska.
Ingår i: Diabetes Care. - : American Diabetes Association. - 1935-5548 .- 0149-5992. ; 31:1, s. 30-35
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective: This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT). Research Design and Methods: A 12-week double-blind, randomized, parallel-group study comparing vildagliptin (50 mg qd) and placebo was conducted in 179 subjects with IGT (2-h glucose= 9.1 mmol/l, A1C= 5.9%). Plasma levels of intact GLP-1 and GIP, glucose, insulin, C-peptide, and glucagon were measured during standard meal tests performed at baseline and Week 12. Insulin secretory rate (ISR) was estimated by C-peptide deconvolution. The between-group differences (vildagliptin - placebo) in the adjusted mean changes from baseline to endpoint in the total and incremental (Delta) AUC(0-2h) for these analytes were assessed by ANCOVA; glucose AUC(0-2h) was the primary outcome variable. Results: Relative to placebo, vildagliptin increased GLP-1 (DeltaAUC, +6.0+/-1.2 pmol/l*h, P<0.001) and GIP (DeltaAUC, +46.8+/-5.4 pmol/l*h, P<0.001) and decreased glucagon (DeltaAUC, -3.0 +/- 1.0 pmol/l*h, P=0.003). Although postprandial insulin levels were unaffected (DeltaAUC, +20.8+/-35.7 pmol/l*h, P=0.561), prandial glucose excursions were reduced (DeltaAUC, -1.0+/-0.3 mmol/l*h, P<0.001), representing approximately 30% decrease relative to placebo. Beta-cell function as assessed by the ISR AUC(0-2h)/glucose AUC(0-2h) was significantly increased (+6.4 +/- 2.0 pmol*min(-1)*m(-2)*mM(-1), P=0.002). Adverse event profiles were similar in the two treatment groups and no hypoglycemia was reported. Conclusions: The known effects of vildagliptin on incretin levels and islet function in type 2 diabetes were reproduced in subjects with IGT with a 32% reduction in postprandial glucose excursions and no evidence of hypoglycemia or weight gain.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy